Azacytidine restores T cell function in AML by modulating DNA methylation.

Area of Science:

• Immunology
• Oncology
• Epigenetics

Background:

• Acute myeloid leukemia (AML) is an aggressive cancer with poor outcomes, often involving T cell dysfunction and exhaustion.
• Current chemotherapy for AML has limited efficacy, with high relapse rates, necessitating alternative therapeutic strategies.
• T cell exhaustion, driven by DNA methylation, is a significant barrier to effective immunotherapy in AML.

Purpose of the Study:

• To investigate the impact of azacytidine (Aza), a hypomethylating agent, on T cell exhaustion in AML.
• To explore the mechanisms by which Aza modulates T cell function and epigenetic states in AML.
• To provide a rationale for combining Aza with T cell-based immunotherapies for AML treatment.

Main Methods:

• Utilized a spontaneous AML mouse model and patient-derived AML samples.
• Administered Aza in vivo and in cultured cells.
• Performed flow cytometry to analyze T cell subsets and function (proliferation).
• Conducted DNA methylation sequencing to assess epigenetic changes and gene expression (TCF7, E2F2).

Main Results:

• Aza treatment reduced tumor burden and modulated CD8+ T cell states, increasing memory subsets and decreasing regulatory T cells (Tregs).
• Aza restored impaired proliferation in both CD4+ and CD8+ T cells.
• Epigenetic analysis revealed Aza-induced hypomethylation and increased expression of stem-like precursor genes TCF7 and E2F2 in T cells.

Conclusions:

• Azacytidine (Aza) treatment remodels epigenetic and functional states in T cells within the AML microenvironment.
• Aza has the potential to reverse T cell exhaustion, enhancing T cell memory and proliferation capacity.
• This study provides a mechanistic basis for combining hypomethylating agents like Aza with immunotherapies to improve outcomes in AML.